Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Glomerulonephritis
Under what circumstances would you consider treating with steroid therapy in a patient with HIV-associated nephropathy?
Related Questions
What are some indications that might lead you to pursue a kidney biopsy in a patient with presumed diabetic kidney disease?
What steroid regimen do you typically use for induction therapy in patients with lupus nephritis?
What are your management strategies for patients with biopsy proven IgA nephropathy with rapidly progressive glomerulonephritis?
What is your approach to immunosuppression in patients with preserved kidney function who are found to have nephrotic syndrome of unknown etiology and cannot safely undergo a kidney biopsy?
How do you approach the management of patients with suspected membranous lupus nephritis who are found to have positive PLA2R antibodies?
Which clinical characteristics would prompt you to consider an oral factor B inhibitor such as iptacopan in the treatment of IgA nephropathy?
What do you feel are the potential barriers to widespread use of obinutuzumab in proliferative lupus nephritis?
What is your threshold to repeat a kidney biopsy in a patient with a history of lupus nephritis who is on maintenance therapy and develops subtle changes in urinary protein excretion or microscopic hematuria?
In patients with lupus nephritis, and MAHA with positive anti-phospholipid autoantibodies, what are the considerations to use or not use anti-coagulation therapy?
Do you wait until serum anti-GBM antibody titers are undetectable before hospital discharge in a patient with anti-GBM antibody disease with renal involvement who is receiving daily plasmapheresis, cyclophosphamide, and steroids?
